Methotrexate‐Induced Nephrotoxicity and Exposure Thresholds in Primary Central Nervous System Lymphoma: A Population PKPD Model
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Ruoyun Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Methotrexate, Central Nervous System Neoplasms, Antimetabolites, Antineoplastic, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
High‐dose methotrexate (HD‐MTX)‐induced nephrotoxicity remains a critical clinical challenge in primary central nervous system lymphoma (PCNSL) treatment, yet quantitative tools for individualized risk prediction are currently lacking. Here, a population pharmacokinetic/pharmacodynamic analysis was performed using 5,918 plasma concentration samples from 743 Chinese adult patients. Nonlinear mixed‐effects modeling was employed to establish toxicodynamic structural models driven by MTX alone, 7‐Hydroxy‐MTX alone, or their combination. Although all models exhibited comparable predictive performance, the MTX linear model was selected as it offered the optimal balance between predictive performance and clinical feasibility. Covariate analysis identified hemoglobin as the most significant predictor, with higher levels correlating with reduced susceptibility to renal injury. To facilitate clinical translation, exposure–toxicity probability curves were constructed, enabling clinicians to identify dynamic concentration thresholds tailored to specific toxicity grades (Grade 1 vs. ≥2 nephrotoxicity) and individualized risk tolerance. Using a 10% risk probability for Grade ≥2 nephrotoxicity as the safety monitoring threshold, the corresponding MTX concentration thresholds at 24, 48, and 72 h were 9.71, 0.81, and 0.26 μmol/L, respectively. This quantitative framework serves as an exploratory tool to complement therapeutic drug monitoring, assisting in the early identification of MTX‐induced renal injury among PCNSL patients with normal to mildly impaired renal function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China.
- Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Ruoyun Wu
Zitieren
APA
Wu, R., Sun, H., Li, Y., Zhu, B., Huo, J., Zhang, D., Sun, X., Zhao, Z., Fu, L., & Mei, S. (2026). Methotrexate‐Induced Nephrotoxicity and Exposure Thresholds in Primary Central Nervous System Lymphoma: A Population PKPD Model. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70305
Vancouver
Wu R, Sun H, Li Y, Zhu B, Huo J, Zhang D, et al. Methotrexate‐Induced Nephrotoxicity and Exposure Thresholds in Primary Central Nervous System Lymphoma: A Population PKPD Model. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70305
BibTeX
@article{Wu2026,
author = {Wu, Ruoyun and Sun, Haiyang and Li, Ying and Zhu, Bin and Huo, Jiping and Zhang, Dongjie and Sun, Xuefei and Zhao, Zhigang and Fu, Lin and Mei, Shenghui},
title = {Methotrexate‐Induced Nephrotoxicity and Exposure Thresholds in Primary Central Nervous System Lymphoma: A Population PKPD Model},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70305}
}
EUVIMED